Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
9 evidence topics · 15 sources
Expected benefit of early treatment: guidelines
“Compared to delayed treatment, early treatment is associated with better outcomes, including faster symptom resolution, shorter episode duration, and greater efficacy, regardless of the severity of the attack.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ODT, regardless of HAE endotype, reduces the risks of asphyxiation, abdominal symptoms, and functional impairment of the limbs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Core outcome set for acute treatment trials
“In the second round, a consensus of 90% or greater was achieved on a core outcome set consisting of five key outcomes: change in overall symptom severity at one predetermined time point between 15 minutes and 4 hours after treatment, time to end of progression of all symptoms, the need for rescue medication during the entire attack, impairment of daily activities, and treatment satisfaction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Attack duration with and without on-demand treatment: prospective cohorts
“Both icatibant and pdC1-INH significantly reduced attack duration compared with no treatment (median times from onset 7, 10 and 47 hours, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median attack duration (data available for 2393 attacks) with approved therapies was 10 h, significantly shorter than without treatment (45 h) or with tranexamic acid (38 h).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median time from onset of symptoms to drug administration was 1 h with icatibant and 2 h with pd-C1INH and median time from drug administration to complete resolution was 5.5 and 8 h, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to symptom relief and resolution with oral sebetralstat: phase 3 trial
“The time to the beginning of symptom relief with the 300-mg dose and the 600-mg dose was faster than with placebo (P<0.001 and P = 0.001 for the two comparisons, respectively), with median times of 1.61 hours (interquartile range, 0.78 to 7.04), 1.79 hours (1.02 to 3.79), and 6.72 hours (1.34 to >12), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of attacks with complete resolution within 24 hours was 42.5% with the 300-mg dose, 49.5% with the 600-mg dose, and 27.4% with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to symptom relief with oral sebetralstat during long-term prophylaxis: open-label extension
“Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deucrictibant outcomes in relation to other on-demand agents: RAPIDe-3 discussion
Reduced emergency department use with self-administration and on-demand access
“Data suggest that self-administration of icatibant reduces and delays the need for Emergency Department visits, which are typically required when attacks affect critical anatomical sites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Burden of disease showed significant improvement in all domains except worry about children inheriting HAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nevertheless, our study shows that a substantial burden of illness remains for HAE patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes after delayed treatment: patient surveys
“Time to treatment paralleled changes in attack severity (33% mild attacks treated in <1 hour vs 67% in ≥1 hour, progressed to moderate/severe) and mean duration (<1 hour: 0.7 day; >8 hours: 2.7 days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When asked how long it usually takes to feel in control of their HAE attacks after on-demand treatment, respondents reported a mean time of 2.2 h (SD: 5.1) post-treatment, with those who treat early (less than 1 h) reporting 1.4 h (SD: 1.1) and those who delay on-demand treatment reporting 2.9 h (SD: 6.7) (Fig. 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote